# To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults

> **NCT04885361** · PHASE1 · UNKNOWN · sponsor: **OSE Immunotherapeutics** · enrollment: 48 (estimated)

## Conditions studied

- Coronavirus Disease (COVID-19)

## Interventions

- **BIOLOGICAL:** CoVepiT (OSE13E)

## Key facts

- **NCT ID:** NCT04885361
- **Lead sponsor:** OSE Immunotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-26
- **Primary completion:** 2021-09-30
- **Final completion:** 2022-03-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2021-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04885361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04885361, "To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04885361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*